Evaluation of safety and efficacy of adipose-derived stem cells in rat myocardial infarction model using hexadecyl-4-[124I]iodobenzoate for cell tracking. (February 2016)

• Record Type: Journal Article
• Authors: Kim, Min Hwan; Lee, Kyo Chul; An, Gwang Il; Woo, Sang-Keun; Park, Noh Won; Kim, Byung Il; Eom, Ki Dong; Kim, Kwang Il; Lee, Tae Sup; Kim, Chan Wha; Yoo, Jeongsoo; Kang, Joo Hyun; Lee, Yong Jin
• Is Part Of: Applied radiation and isotopes. Volume 108(2016:Feb.)
• Page Start: 116
• Page End: 123
• Publication Date: 2016-02
• Subjects: Adipose-derived stem cells -- Hexadecyl-4-[124I]iodobenzoate -- Direct labeling agent -- Microarray -- Myocardial infarction; Radiology -- Periodicals; Radiation -- Industrial applications -- Periodicals; Nuclear chemistry -- Periodicals; Internet resource; Periodical; 660.298
• DOI: 10.1016/j.apradiso.2015.12.039
• Languages: English
• ISSNs: 0969-8043

Abstract

Abstract: This study was aimed to evaluate the effect of 124 I-labeling with hexadecyl-4-iodobenzoate (HIB) on gene expression related to cell cycle, DNA repair, transcription, proliferation and differentiation of adipose-derived stem cells (ADSCs). [ 124 I]HIB showed high labeling efficiency with ADSCs (51.3±1.3%, 0.3–2.0 Bq/cell) and there is no morphological change of ADSCs. In the microarray analysis of gene expression pattern, differences were not observed between non-labeled and [ 124 I]HIB-labeled ADSCs. We demonstrated that 124 I-labeling with HIB did not affect the biological properties of ADSCs. Highlights: There was no significant alteration of gene expression in [ 124 I]HIB-labeled ADSCs. ADSCs therapy using radioisotope ( 124 I) attenuated cardiac remodeling by MI. Angiogenesis and cardiac related genes are up-regulated by ADSC therapy in MI. Iodine-124 has no adverse events for safety and therapeutic potential of ADSCs in MI.